NOVOCART 3D is part of a U.S. Food and Drug Administration Investigational New Drug Phase 3 randomized, multicenter study. The product is a matrix-induced autologous chondrocyte product, designed to repair articular cartilage defects of the knee.
Kenneth R. Zaslav, MD, an orthopedic surgeon with Advanced Orthopedics in Richmond, Va., performed the implantation during a knee surgery.
Aesculap Biologics, a division of Aesculap, is focused on biological approaches for the repair and regeneration of diseased or damaged tissues.
More articles on devices:
8 things to know about the Asia-Pacific minimally invasive spine device market
15 spine devices receive FDA 510(k) clearance in August
Former ArthroCare execs get 10+ years in prison for fraud costing shareholders $750M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
